Generated by AI
Scinai Immunotherapeutics Ltd. American Depositary Shares represent an ownership interest in a biopharmaceutical company focused on inflammation and immunology therapies. Scinai Immunotherapeutics develops biological products aimed at infectious and autoimmune diseases, including nanosized antibody programs and other immunology-focused candidates. The company also operates a contract development and manufacturing organization, providing development and manufacturing services for biotechnology clients from early-stage work through clinical production. Its business spans both internal research and development and third-party biomanufacturing, giving it a dual role in the life sciences market. Scinai Immunotherapeutics Ltd. is headquartered in Jerusalem, Israel, and its ADS structure allows investors to access the company through depositary shares rather than ordinary shares directly.
WebsiteJerusalem BioPark Building
Jerusalem
Israel
The latest articles about SCNI.
--Scinai Immunotherapeutics Ltd. today issued the following letter to shareholders from Chief Executive Officer Amir Reichman. Our new agreement with a U.S.- based, Nasdaq-listed biopharmaceutical company includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. As of October 20, 2026, our Committed...
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 13's posts. Generated by AI.
Summary of Jun 17's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about SCNI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.